Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

Onconova Therapeutics stock price, quote, forecast and news

ONTX
US68232V4059
A2N6RH

Price

0.34
Today +/-
+0.01
Today %
+2.68 %
P

Onconova Therapeutics stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Onconova Therapeutics stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Onconova Therapeutics stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Onconova Therapeutics stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Onconova Therapeutics's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Onconova Therapeutics Stock Price History

DateOnconova Therapeutics Price
9/12/20240.34 undefined
9/11/20240.33 undefined
9/10/20240.34 undefined
9/9/20240.34 undefined
9/6/20240.36 undefined
9/5/20240.35 undefined
9/4/20240.37 undefined
9/3/20240.37 undefined
8/30/20240.37 undefined
8/29/20240.37 undefined
8/28/20240.35 undefined
8/27/20240.38 undefined
8/26/20240.37 undefined
8/23/20240.37 undefined
8/22/20240.36 undefined
8/21/20240.37 undefined
8/20/20240.36 undefined
8/19/20240.39 undefined
8/16/20240.38 undefined

Onconova Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Onconova Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Onconova Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Onconova Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Onconova Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Onconova Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Onconova Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Onconova Therapeutics’s growth potential.

Onconova Therapeutics Revenue, EBIT and net profit per share

DateOnconova Therapeutics RevenueOnconova Therapeutics EBITOnconova Therapeutics Net Income
2026e195,935.3 undefined-14.02 M undefined-17.99 M undefined
2025e306,000 undefined-30.29 M undefined-18.42 M undefined
2024e265,200 undefined-24.89 M undefined-18.85 M undefined
2023226,000 undefined-20.3 M undefined-18.95 M undefined
2022226,000 undefined-19.63 M undefined-18.96 M undefined
2021226,000 undefined-16.5 M undefined-16.16 M undefined
2020230,000 undefined-24.99 M undefined-25.16 M undefined
20192.18 M undefined-21.7 M undefined-21.5 M undefined
20181.23 M undefined-23.28 M undefined-20.57 M undefined
2017790,000 undefined-25.74 M undefined-24.09 M undefined
20165.55 M undefined-23.7 M undefined-19.67 M undefined
201511.46 M undefined-23.97 M undefined-23.98 M undefined
2014800,000 undefined-63.74 M undefined-63.68 M undefined
20134.75 M undefined-62.22 M undefined-64.86 M undefined
201246.19 M undefined-22.28 M undefined-33.87 M undefined
20111.49 M undefined-27.57 M undefined-30.31 M undefined

Onconova Therapeutics Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (M)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (M)EBIT (M)EBIT MARGIN (%)NET INCOME (M)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
20112012201320142015201620172018201920202021202220232024e2025e2026e
146401150120000000
-4,500.00-91.30---54.55--100.00-------
----------------
0000000000000000
-27-22-62-63-23-23-25-23-21-24-16-19-20-24-30-14
-2,700.00-47.83-1,550.00--209.09-460.00--2,300.00-1,050.00-------
-30-33-64-63-23-19-24-20-21-25-16-18-18-18-18-17
-10.0093.94-1.56-63.49-17.3926.32-16.675.0019.05-36.0012.50----5.56
0000.010.010.020.040.270.9611.616.8320.9120.99000
----------------
Details

Keystats

ⓘ

Revenue and Growth

The Onconova Therapeutics Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Onconova Therapeutics is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (M)RECEIVABLES (M)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (M)TANGIBLE ASSETS (k)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (k)NON-CURRENT ASSETS (k)TOTAL ASSETS (M)LIABILITIESCOMMON STOCK (M)ADDITIONAL PAID-IN CAPITAL (M)RETAINED EARNINGS (M)OTHER EQUITY (M)UNREAL. GAINS/LOSSES (M)EQUITY (M)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (M)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (M)SHORT-TERM REC. (M)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (M)TOTAL CAPITAL (M)
2011201220132014201520162017201820192020202120222023
                         
2.781.510043.619.821.441722.71955.0738.7620.82
00001.500.100.100.030.030.02
0000000000000
0000000000000
0.71.74.43.31.91.60.80.80.60.70.330.561.82
3.483.2104.446.923.2234.917.823.419.755.4339.3522.66
5005006004002002001000100100382422
0000000000000
0000000000000
0000000000000
0000000000000
10010010000001002002001011
600600700400200200100100300300482523
483.8105.147.323.423.2517.923.72055.4839.3722.68
                         
120201.30.20.20.30.10.10.11.11.90.210.210.21
010311.1317.1328.3342.5350.5387.2413.9432.9490.64491.82493.12
-138.4-168.4-230.9-294.6-318.6-338.2-362.3-381.9-403.4-428.6-444.72-463.68-482.63
0000000000-0.01-0.03-0.02
0000000000000
-18.442.980.422.7104.4-11.75.411.66.246.1228.3110.67
5.65.53.743.45.36.240.54.82.763.865.62
1.73.95.55.83.74.13.24.27.34.82.983.783.2
4.815.91.10.50.50.70.60.20.50.40.380.410.4
0000000000000
0000000000000
12.125.310.310.37.610.1108.48.3106.128.059.22
0000000000000
0000000000000
10.815.513.913.557.95.94.13.83.83.243.022.79
10.815.513.913.557.95.94.13.83.83.243.022.79
22.940.824.223.812.61815.912.512.113.89.3611.0612.01
4.583.7104.646.522.622.44.217.923.72055.4839.3722.68
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Onconova Therapeutics provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Onconova Therapeutics's financial health and stability.

Assets

Onconova Therapeutics's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Onconova Therapeutics must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Onconova Therapeutics after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Onconova Therapeutics's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (M)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (k)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (M)CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (M)NET CHANGE IN EQUITY (M)CASH FLOW FROM FINANCING ACTIVITIES (M)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (M)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
201120122013201420152016201720182019202020212022
-26-29-62-63-24-19-24-20-21-25-16-18
000000000000
000000000000
139-70-1130-101-31
-12175300-10001
000000000000
000000000000
-14,0001,000-61,000-57,000-31,000-15,000-23,000-22,000-20,000-23,000-19,000-16,000
000000000000
00-403900000000
00-394000000000
000000000000
0250000000000
7487907176352619550
9778017176352619550
230000000000
000000000000
-478-21-16-231-17125-336-16
-14.431.35-61.99-57.88-31.24-15.81-23.82-22.7-20.89-23.1-19.49-16.29
000000000000

Onconova Therapeutics stock margins

The Onconova Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Onconova Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Onconova Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Onconova Therapeutics's sales revenue. A higher gross margin percentage indicates that the Onconova Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Onconova Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Onconova Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Onconova Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Onconova Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Onconova Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Onconova Therapeutics Margin History

Onconova Therapeutics Gross marginOnconova Therapeutics Profit marginOnconova Therapeutics EBIT marginOnconova Therapeutics Profit margin
2026e0 %-7,152.91 %-9,183.03 %
2025e0 %-9,900 %-6,020 %
2024e0 %-9,384.62 %-7,107.69 %
20230 %-8,981.42 %-8,384.07 %
20220 %-8,684.51 %-8,391.15 %
20210 %-7,299.12 %-7,151.77 %
20200 %-10,865.22 %-10,939.13 %
20190 %-995.41 %-986.24 %
20180 %-1,892.68 %-1,672.36 %
20170 %-3,258.23 %-3,049.37 %
20160 %-427.03 %-354.41 %
20150 %-209.16 %-209.25 %
20140 %-7,967.5 %-7,960 %
20130 %-1,309.89 %-1,365.47 %
20120 %-48.24 %-73.33 %
20110 %-1,850.34 %-2,034.23 %

Onconova Therapeutics Stock Sales Revenue, EBIT, Earnings per Share

The Onconova Therapeutics earnings per share therefore indicates how much revenue Onconova Therapeutics has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Onconova Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Onconova Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Onconova Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Onconova Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Onconova Therapeutics Revenue, EBIT and net profit per share

DateOnconova Therapeutics Sales per ShareOnconova Therapeutics EBIT per shareOnconova Therapeutics Earnings per Share
2026e0.01 undefined0 undefined-0.86 undefined
2025e0.01 undefined0 undefined-0.88 undefined
2024e0.01 undefined0 undefined-0.9 undefined
20230.01 undefined-0.97 undefined-0.9 undefined
20220.01 undefined-0.94 undefined-0.91 undefined
20210.01 undefined-0.98 undefined-0.96 undefined
20200.02 undefined-2.15 undefined-2.17 undefined
20192.27 undefined-22.6 undefined-22.4 undefined
20184.56 undefined-86.22 undefined-76.19 undefined
201719.75 undefined-643.5 undefined-602.25 undefined
2016277.5 undefined-1,185 undefined-983.5 undefined
20151,146 undefined-2,397 undefined-2,398 undefined
201480 undefined-6,374 undefined-6,368 undefined
20130 undefined0 undefined0 undefined
20120 undefined0 undefined0 undefined
20110 undefined0 undefined0 undefined

Onconova Therapeutics business model

Onconova Therapeutics Inc. is a biopharmaceutical company focused on the development of drugs and therapies for the treatment of cancer. The company was founded in Pennsylvania in 1998 and is headquartered in Newtown, Pennsylvania. In 2013, the company went public and was listed on the NASDAQ. The history of Onconova Therapeutics began with the discovery of a new class of compounds known as precursor nucleotide analogs. These compounds were developed in collaboration with the National Cancer Institute (NCI) and showed promising results in cancer treatment. Onconova aims to develop innovative cancer therapies that allow for targeted attack on cancer cells without damaging healthy cells in the body. The company's research and development efforts focus on the discovery and development of new compounds and therapy approaches, as well as improving existing cancer treatments. The business model of Onconova Therapeutics is centered around building long-term partnerships with leading pharmaceutical companies, academic institutions, and research facilities. The company works closely with these partners to develop innovative therapies and drugs that meet the needs of cancer patients. Onconova has divided its product development into multiple areas to investigate the potential of its compounds in various therapy areas. The two main areas of focus for the company are myeloproliferative neoplasms (MPN) and oncology. Myeloproliferative neoplasms are a group of blood cancers that affect the bone marrow. Onconova Therapeutics has developed a promising class of compounds known as selective oral inhibitors (SOIs) that target the main drivers of MPNs and have shown positive results in clinical trials. The oncology division of the company focuses on the development of compounds for the treatment of solid tumors. Onconova has developed a targeted cancer therapy that focuses on inhibiting WNT signaling. This approach aims to allow for selective attack on cancer cells without damaging healthy cells in the body. In addition to these two areas, the company is also working on the development of compounds for the treatment of advanced tumors, lung cancer, and other types of cancer. The main product of Onconova Therapeutics is Rigosertib. Rigosertib is a selective oral inhibitor (SOI) specifically developed for the treatment of myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). The drug is currently in the final phase III of testing by the FDA. In addition to Rigosertib, Onconova is conducting further clinical studies to investigate the effectiveness and safety of its cancer drugs. The company aims to develop innovative therapy options that help cancer patients overcome their disease and lead longer lives without the harmful effects of conventional cancer therapies. Overall, Onconova Therapeutics Inc. has a promising future as an innovative biopharmaceutical company. By continuing its research and development activities in multiple areas and developing new compounds and therapies, Onconova will continually contribute to improving the lives of cancer patients. Onconova Therapeutics is one of the most popular companies on Eulerpool.com.

Onconova Therapeutics SWOT Analysis

Strengths

Onconova Therapeutics Inc has a strong and experienced management team with significant expertise in the biopharmaceutical industry.

The company's primary strength lies in its innovative drug pipeline, with several promising candidates in various stages of development.

Weaknesses

Onconova Therapeutics Inc has a relatively small research and development budget compared to some of its larger competitors, which could limit its ability to accelerate the development of its pipeline.

The company heavily relies on external financing to support its ongoing operations, which introduces financial risk and potential dilution for existing shareholders.

Opportunities

Onconova Therapeutics Inc operates in a growing market for cancer therapeutics, with increasing demand for innovative and targeted treatments.

The recent advancements in technology and genomics provide an opportunity for the company to identify and develop personalized therapies for specific patient populations.

Threats

The biopharmaceutical industry is highly competitive, with larger and more established companies having more resources and market presence.

Regulatory hurdles and approval processes pose a significant threat, as delays or failures could hinder the commercialization of the company's pipeline candidates.

Onconova Therapeutics Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Onconova Therapeutics historical P/E ratio, EBIT, and P/S ratio.

Onconova Therapeutics shares outstanding

The number of shares was Onconova Therapeutics in 2023 — This indicates how many shares 20.989 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Onconova Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Onconova Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Onconova Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Onconova Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Onconova Therapeutics Stock splits

In Onconova Therapeutics's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for Onconova Therapeutics.

Onconova Therapeutics latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
9/30/2023-0.3 -0.23  (22.24 %)2023 Q3
6/30/2023-0.32 -0.2  (37.26 %)2023 Q2
3/31/2023-0.3 -0.28  (7.74 %)2023 Q1
12/31/2022-0.29 -0.26  (8.96 %)2022 Q4
9/30/2022-0.22 -0.26  (-19.93 %)2022 Q3
6/30/2022-0.2 -0.19  (5.71 %)2022 Q2
3/31/2022-0.19 -0.2  (-3.2 %)2022 Q1
12/31/2021-0.28 -0.15  (45.53 %)2021 Q4
9/30/2021-0.33 -0.22  (33.97 %)2021 Q3
6/30/2021-0.29 -0.27  (7.12 %)2021 Q2
1
2
3
4
...
5

Onconova Therapeutics list of shareholders

%
Name
Stocks
Change
Date
7.83381 % Viriom, Inc.1,645,1001,645,1004/3/2024
4.21682 % TPAV, LLC885,532885,5324/1/2024
3.37437 % The Vanguard Group, Inc.708,618012/31/2023
1.18515 % BlackRock Institutional Trust Company, N.A.248,881012/31/2023
0.95238 % Cautreels (Werner C)200,000200,0004/1/2024
0.94686 % Renaissance Technologies LLC198,84115,14712/31/2023
0.91837 % Geode Capital Management, L.L.C.192,858012/31/2023
0.63922 % Dukes (Iain D)134,237134,2374/1/2024
0.63922 % Savchuk (Nikolay)134,237134,2374/1/2024
0.55886 % Two Sigma Investments, LP117,361-113,11012/31/2023
1
2
3
4
5
...
6

Onconova Therapeutics Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
SymBio Pharmaceuticals Stock
SymBio Pharmaceuticals
SupplierCustomer0,210,740,200,710,77-0,06
Knight Therapeutics Stock
Knight Therapeutics
SupplierCustomer0,13-0,15-0,10-0,46-0,360,30
1

Most common questions regarding Onconova Therapeutics

What values and corporate philosophy does Onconova Therapeutics represent?

Onconova Therapeutics Inc represents values of innovation, dedication to improving cancer treatments, and commitment to patient care. The company's corporate philosophy revolves around developing novel therapeutics to address unmet medical needs and enhancing the overall quality of life for cancer patients. With a focus on targeted therapies and precision medicine, Onconova Therapeutics Inc aims to revolutionize cancer treatment through groundbreaking research and clinical advancements. The company's strong belief in scientific excellence, collaboration with key stakeholders, and a patient-centric approach drives its pursuit of transforming the landscape of cancer care.

In which countries and regions is Onconova Therapeutics primarily present?

Onconova Therapeutics Inc is primarily present in the United States.

What significant milestones has the company Onconova Therapeutics achieved?

Onconova Therapeutics Inc has achieved significant milestones in its journey. The company obtained Fast Track designation from the U.S. FDA for its drug rigosertib, which is being developed to treat Myelodysplastic Syndromes and pancreatic cancer. Onconova also conducted a pivotal Phase 3 ONTIME trial for rigosertib in patients with Myelodysplastic Syndromes, reaching its primary endpoint. Additionally, the company successfully completed its Phase 2 trial of Oral Rigosertib in combination with Azacitidine for Myelodysplastic Syndromes. These accomplishments demonstrate Onconova's commitment to advancing innovative therapies and improving treatment options for patients.

What is the history and background of the company Onconova Therapeutics?

Onconova Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for the treatment of cancer. Founded in 1998, the company is headquartered in Newtown, Pennsylvania. Onconova is dedicated to discovering and advancing innovative molecules that target critical cellular pathways involved in cancer progression. Its lead product candidate, Rigosertib, is being evaluated in various clinical trials for the treatment of myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), and other solid tumors. Onconova Therapeutics Inc has established strategic collaborations with global pharmaceutical companies for the development and commercialization of its pipeline.

Who are the main competitors of Onconova Therapeutics in the market?

The main competitors of Onconova Therapeutics Inc in the market include pharmaceutical companies such as Novartis, Pfizer, and Merck. These companies, like Onconova Therapeutics Inc, operate in the biotechnology sector, focusing on the development and commercialization of innovative therapies for various diseases, particularly cancer. The competition among these industry players leads to a dynamic market landscape where each company strives to bring forth groundbreaking treatments and gain a competitive edge in the field.

In which industries is Onconova Therapeutics primarily active?

Onconova Therapeutics Inc is primarily active in the pharmaceutical and biotechnology industries.

What is the business model of Onconova Therapeutics?

The business model of Onconova Therapeutics Inc revolves around developing and commercializing novel therapies for cancer through targeted intervention at the cellular level. They focus on discovering and developing small molecules that target key cellular pathways involved in cancer progression. By advancing their pipeline of drug candidates, Onconova aims to provide innovative treatment options for patients battling various types of cancer. They employ a research-driven approach to identify and validate potential therapeutic targets, followed by rigorous clinical development and regulatory processes. Onconova Therapeutics Inc strives to improve patient outcomes and address unmet medical needs in the oncology field.

What is the P/E ratio of Onconova Therapeutics 2024?

The Onconova Therapeutics P/E ratio is -0.38.

What is the P/S ratio of Onconova Therapeutics 2024?

The Onconova Therapeutics P/S ratio is 26.91.

What is the AlleAktien quality score of Onconova Therapeutics?

The AlleAktien quality score for Onconova Therapeutics is 2/10.

What is the revenue of Onconova Therapeutics 2024?

The expected Onconova Therapeutics revenue is 265,200 USD.

How high is the profit of Onconova Therapeutics 2024?

The expected Onconova Therapeutics profit is -18.85 M USD.

What is the business model of Onconova Therapeutics

Onconova Therapeutics Inc is a biopharmaceutical company that develops innovative drugs for the treatment of cancer and chronic bone marrow diseases. It is headquartered in Newtown, Pennsylvania, and also has branches in Germany and India. The business model of Onconova Therapeutics is based on the joint development of innovative drugs for the treatment of serious diseases in close collaboration with partner companies and research institutions. The company follows a customized drug development approach, offering a wide range of tailored drugs that can be ordered by customers depending on their specific medical needs. Onconova Therapeutics is divided into two business segments: the Oncology segment and the Onconova-assisted Research segment. In the Oncology segment, the company focuses on the development of drugs for the treatment of solid tumors and hematological cancers. This includes ongoing research programs that specifically target innovative drug candidates. Onconova-assisted Research was established as a research initiative that invests in innovative technologies for medical development in various disease areas. This initiative provides support for customer development programs that want to leverage the progress of Onconova Therapeutics to advance their own drug candidates in clinical trials. Onconova Therapeutics also offers a range of products, including Rigors Stimulator (a chemical-free technology for generating early warning signals for infections) and OTP201 (a substance developed for use in combination cancer chemotherapy). The company has achieved several key milestones, including completing funding rounds, establishing partnerships with pharmaceutical companies (such as Teva Pharmaceuticals Industries Ltd), and obtaining patents for its core competencies. In terms of operational results, Onconova Therapeutics showed strong financial performance in 2019, with a 45 percent increase in cash balance compared to the previous year. The company has focused on expanding into new markets in Europe and Asia and believes this will contribute to consistent growth. Overall, Onconova Therapeutics offers a wide portfolio of innovative drugs and technologies for the treatment of cancer and bone diseases. The company is dedicated to customized drug development and strives to meet the diverse needs of its customers. With the continuation of its research initiative and the expansion into new markets in Europe and Asia, Onconova Therapeutics is well positioned to remain innovative and promote the growth of the company in the coming years.

What is the Onconova Therapeutics dividend?

Onconova Therapeutics pays a dividend of 0 USD distributed over payouts per year.

How often does Onconova Therapeutics pay dividends?

The dividend cannot currently be calculated for Onconova Therapeutics or the company does not pay out a dividend.

What is the Onconova Therapeutics ISIN?

The ISIN of Onconova Therapeutics is US68232V4059.

What is the Onconova Therapeutics WKN?

The WKN of Onconova Therapeutics is A2N6RH.

What is the Onconova Therapeutics ticker?

The ticker of Onconova Therapeutics is ONTX.

How much dividend does Onconova Therapeutics pay?

Over the past 12 months, Onconova Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Onconova Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Onconova Therapeutics?

The current dividend yield of Onconova Therapeutics is .

When does Onconova Therapeutics pay dividends?

Onconova Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Onconova Therapeutics?

Onconova Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Onconova Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Onconova Therapeutics located?

Onconova Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Onconova Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Onconova Therapeutics from 9/14/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/14/2024.

When did Onconova Therapeutics pay the last dividend?

The last dividend was paid out on 9/14/2024.

What was the dividend of Onconova Therapeutics in the year 2023?

In the year 2023, Onconova Therapeutics distributed 0 USD as dividends.

In which currency does Onconova Therapeutics pay out the dividend?

The dividends of Onconova Therapeutics are distributed in USD.

All fundamentals about Onconova Therapeutics

Our stock analysis for Onconova Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Onconova Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.